AbbVie’s AQUIPTA[®]▼(atogepant) receives MHRA marketing authorisation for the prevention of migraines in adults
PRESS RELEASE - For UK consumer, trade and medical media only · The oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) is licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain for the prophylaxis of migraine in adults who have at least four migraine days per month.[1] · The marketing authorisation is based on results from two pivotal Phase 3 studies in which the treatment demonstrated significant reduction in mean monthly migraine days from baseline across 12 weeks.[1-5] · The news closely follows the European